Drug Combination Details
| General Information of the Combination (ID: C89196) | |||||
|---|---|---|---|---|---|
| Name | Dicoumarol NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | KKU-100 | CVCL_3996 | Hilar cholangiocarcinoma | Homo sapiens | ||
| KKU-OCA17 | CVCL_M265 | Intrahepatic cholangiocarcinoma | Homo sapiens | |||
| KKU-213B | CVCL_M264 | Cholangiocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
NQO1 may be important in sensitizing cells to anticancer drugs and inhibition of NQO1 may be a strategy for the treatment of CCA. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol. 2010 May 21;16(19):2362-70. | |||
